Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG NAING

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1104837590
CMS profile
366226
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,639.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $2,639.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG NAING

NPI 1104837590 · CMS profile ID 366226

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,639.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $2,639.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835545359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.43 16
PY2020 $211.34 1
PY2021 $2,639.00 1
PY2022 $5,205.00 2
PY2023 $3,375.00 2
PY2025 $4,703.88 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,918,481.53 469
PY2024 Recipient $4,531.10 4
PY2024 Principal investigator $4,445,667.71 159
PY2023 Principal investigator $4,761,955.67 97
PY2022 Principal investigator $3,708,621.77 334
PY2021 Principal investigator $5,802,399.26 154
PY2020 Recipient $2,459.66 4
PY2020 Principal investigator $1,927,221.68 148
PY2019 Principal investigator $5,972,979.75 356

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

154 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $498,432.00 12/31/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 848758903
Principal investigator 1 Merck Sharp & Dohme Corporation $1,007,500.00 12/31/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 848767285
Principal investigator 1 PFIZER INC. $12,682.29 12/23/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832574597
Principal investigator 1 BioNTech SE $2,648.60 12/22/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 851137815
Principal investigator 1 BioNTech SE $20,039.60 12/16/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 851137735
Principal investigator 1 EMD Serono, Inc. $104.80 12/16/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842919825
Principal investigator 1 BioNTech SE $163,054.46 12/09/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137941
Principal investigator 1 PFIZER INC. $3,337.17 12/08/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832574607
Principal investigator 1 BioNTech SE $53,750.00 11/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137939
Principal investigator 1 PFIZER INC. $46,350.71 11/24/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680553
Principal investigator 1 EMD Serono, Inc. $51,475.00 11/22/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 842914503
Principal investigator 1 BioNTech SE $59,834.90 11/18/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 851137603
Principal investigator 1 Incyte Corporation $1,862.00 11/16/2021 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 831148601
Principal investigator 1 BioNTech SE $112,533.93 11/10/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137937
Principal investigator 1 SANOFI US SERVICES INC. $46,669.25 11/09/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 838651021
Principal investigator 1 PFIZER INC. $14,145.36 11/05/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680541
Principal investigator 1 Incyte Corporation $1,352.70 10/29/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831057047
Principal investigator 1 Incyte Corporation $3,316.50 10/22/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831057041
Principal investigator 1 BioNTech SE $94,492.80 10/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 851137561
Principal investigator 1 EMD Serono, Inc. $1,441.60 10/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842918317
Principal investigator 1 EMD Serono, Inc. $1,802.00 10/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842918551
Principal investigator 1 PFIZER INC. $18,694.84 10/21/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680003
Principal investigator 1 PFIZER INC. $3,682.85 10/08/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832681077
Principal investigator 1 BioNTech SE $11,457.38 09/23/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137935
Principal investigator 1 PFIZER INC. $5,728.79 09/22/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680015
Principal investigator 1 SANOFI US SERVICES INC. $149,339.05 09/14/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 838651017
Principal investigator 1 PFIZER INC. $859.91 09/04/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832681927
Principal investigator 1 Incyte Corporation $1,537.20 09/03/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831075487
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,911.50 08/23/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IIB TMB High Pan Tumor FA for tTMB No dispute reported 06/30/2026 819882103
Principal investigator 1 PFIZER INC. $3,340.71 08/21/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680831
Principal investigator 1 BioNTech SE $30,091.72 08/19/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137933
Principal investigator 1 EMD Serono, Inc. $1,802.00 08/19/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842910819
Principal investigator 1 Incyte Corporation $25.02 08/09/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831057011
Principal investigator 1 Incyte Corporation $20.26 08/09/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831057017
Principal investigator 1 Incyte Corporation $116.40 08/09/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831057023
Principal investigator 1 Incyte Corporation $10,593.90 08/06/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831075463
Principal investigator 1 PFIZER INC. $8,498.15 08/06/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832679759
Principal investigator 1 BioNTech SE $15,695.23 07/29/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137931
Principal investigator 1 Karyopharm Therapeutics Inc. $286,831.13 07/23/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies No dispute reported 06/30/2026 845834767
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $129.42 07/15/2021 Non-covered Recipient Entity
University Of Texas Md Anderson Cancer Center-Investigational Cancer Therapeutics
Phase I IIA FIH CCR8 Mono Combo No dispute reported 06/30/2026 819904663
Principal investigator 1 PFIZER INC. $34,561.98 07/09/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680841
Principal investigator 1 Deciphera Pharmaceuticals Inc. $139.00 07/07/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 827891893
Principal investigator 1 Incyte Corporation $12,746.70 06/30/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831075221
Principal investigator 1 EMD Serono, Inc. $23,428.80 06/28/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 842897513
Principal investigator 1 Incyte Corporation $2,436.07 06/28/2021 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831148597
Principal investigator 1 Incyte Corporation $264.29 06/28/2021 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831148599
Principal investigator 1 BioNTech SE $2,619.82 06/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137929
Principal investigator 1 PFIZER INC. $3,682.85 06/22/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680819
Principal investigator 1 BioNTech SE $35,827.44 06/17/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 851137927
Principal investigator 1 EMD Serono, Inc. $45,537.30 06/17/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 842897653
Principal investigator 1 Incyte Corporation $1,011.60 06/11/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 831075197
Principal investigator 1 Incyte Corporation $2,089.80 06/11/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 831075203
Principal investigator 1 PFIZER INC. $12,141.86 06/05/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832682153
Principal investigator 1 PFIZER INC. $2,272.50 05/21/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832681915
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842928643
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842928765
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842928839
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842928895
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842928905
Principal investigator 1 EMD Serono, Inc. $1,802.00 05/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842929029
Principal investigator 1 Incyte Corporation $5,904.00 05/10/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831075149
Principal investigator 1 PFIZER INC. $15,281.13 05/07/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832679773
Principal investigator 1 PFIZER INC. $22,923.79 04/21/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832681941
Principal investigator 1 SANOFI US SERVICES INC. $126,597.30 04/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 838660865
Principal investigator 1 Incyte Corporation $44.75 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056311
Principal investigator 1 Incyte Corporation $251.40 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056315
Principal investigator 1 Incyte Corporation $43.20 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056321
Principal investigator 1 Incyte Corporation $89.50 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056327
Principal investigator 1 Incyte Corporation $125.70 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056333
Principal investigator 1 Incyte Corporation $54.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056339
Principal investigator 1 Incyte Corporation $27.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056345
Principal investigator 1 Incyte Corporation $71.60 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056351
Principal investigator 1 Incyte Corporation $201.12 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056357
Principal investigator 1 Incyte Corporation $43.20 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056523
Principal investigator 1 Incyte Corporation $43.20 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056527
Principal investigator 1 Incyte Corporation $43.20 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056533
Principal investigator 1 Incyte Corporation $43.20 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056539
Principal investigator 1 Incyte Corporation $27.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056545
Principal investigator 1 Incyte Corporation $27.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056551
Principal investigator 1 Incyte Corporation $54.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056557
Principal investigator 1 Incyte Corporation $54.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056563
Principal investigator 1 Incyte Corporation $54.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056569
Principal investigator 1 Incyte Corporation $54.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056575
Principal investigator 1 Incyte Corporation $27.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056581
Principal investigator 1 Incyte Corporation $27.00 04/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831056587
Principal investigator 1 Novartis Pharmaceuticals Corporation $105,478.94 04/15/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE IB II OPEN LABEL MULTICENTER STUDY OF MCS110 IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 800618649
Principal investigator 1 PFIZER INC. $62,019.65 04/09/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832680025
Principal investigator 1 Incyte Corporation $107.20 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056363
Principal investigator 1 Incyte Corporation $140.64 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056369
Principal investigator 1 Incyte Corporation $51.05 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056375
Principal investigator 1 Incyte Corporation $194.00 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056381
Principal investigator 1 Incyte Corporation $62.55 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056387
Principal investigator 1 Incyte Corporation $61.84 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056393
Principal investigator 1 Incyte Corporation $107.20 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056593
Principal investigator 1 Incyte Corporation $62.55 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056599
Principal investigator 1 Incyte Corporation $51.05 04/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056605
Principal investigator 1 EMD Serono, Inc. $1,802.00 04/06/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842930629
Principal investigator 1 EMD Serono, Inc. $1,802.00 04/06/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842930705
Principal investigator 1 EMD Serono, Inc. $1,802.00 04/06/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842930711
Principal investigator 1 Incyte Corporation $19,489.50 03/29/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074523
Principal investigator 1 Karyopharm Therapeutics Inc. $1,080,000.00 03/26/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies No dispute reported 06/30/2026 845834769
Principal investigator 1 PFIZER INC. $2,405.80 03/24/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832679783
Principal investigator 1 Novartis Pharmaceuticals Corporation $95,032.74 03/17/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 800617283
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $277,272.27 03/05/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 819882133
Principal investigator 1 PFIZER INC. $73,364.57 03/05/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832681091
Principal investigator 1 Incyte Corporation $25.00 02/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 831114731
Principal investigator 1 Incyte Corporation $33.00 02/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 831114737
Principal investigator 1 Incyte Corporation $33.00 02/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 831114743
Principal investigator 1 Incyte Corporation $33.00 02/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 831114749
Principal investigator 1 Incyte Corporation $33.00 02/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 831114755
Principal investigator 1 Incyte Corporation $33.00 02/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 831114761
Principal investigator 1 Incyte Corporation $1,517.40 02/09/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 831074442
Principal investigator 1 Incyte Corporation $64.32 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056129
Principal investigator 1 Incyte Corporation $75.06 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056135
Principal investigator 1 Incyte Corporation $30.63 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056141
Principal investigator 1 Incyte Corporation $91.89 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056147
Principal investigator 1 Incyte Corporation $116.40 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056153
Principal investigator 1 Incyte Corporation $6.39 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056159
Principal investigator 1 Incyte Corporation $2.84 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056165
Principal investigator 1 Incyte Corporation $30.92 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056171
Principal investigator 1 Incyte Corporation $35.16 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056177
Principal investigator 1 Incyte Corporation $12.30 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056183
Principal investigator 1 Incyte Corporation $10.20 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056187
Principal investigator 1 Incyte Corporation $20.26 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056194
Principal investigator 1 Incyte Corporation $1.08 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056201
Principal investigator 1 Incyte Corporation $12.24 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056207
Principal investigator 1 Incyte Corporation $15.64 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056213
Principal investigator 1 Incyte Corporation $65.89 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056219
Principal investigator 1 Incyte Corporation $24.08 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056225
Principal investigator 1 Incyte Corporation $1.56 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056231
Principal investigator 1 Incyte Corporation $2.97 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056237
Principal investigator 1 Incyte Corporation $64.32 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056243
Principal investigator 1 Incyte Corporation $75.06 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056247
Principal investigator 1 Incyte Corporation $6.39 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056255
Principal investigator 1 Incyte Corporation $20.26 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056261
Principal investigator 1 Incyte Corporation $1.08 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056267
Principal investigator 1 Incyte Corporation $12.24 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056273
Principal investigator 1 Incyte Corporation $24.08 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056279
Principal investigator 1 Incyte Corporation $2.97 02/08/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831056286
Principal investigator 1 Karyopharm Therapeutics Inc. $48,531.12 01/28/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or non-Hodgkins Lymphoma No dispute reported 06/30/2026 845834753
Principal investigator 1 Incyte Corporation $3,750.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074395
Principal investigator 1 Incyte Corporation $5,625.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074401
Principal investigator 1 Incyte Corporation $1,875.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074407
Principal investigator 1 Incyte Corporation $25,625.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074413
Principal investigator 1 Incyte Corporation $2,500.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074419
Principal investigator 1 Incyte Corporation $1,250.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074425
Principal investigator 1 Incyte Corporation $31.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074431
Principal investigator 1 Incyte Corporation $4,000.00 01/21/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831074437
Principal investigator 1 Novartis Pharmaceuticals Corporation $270,448.94 01/20/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 800618637
Principal investigator 1 EMD Serono, Inc. $8,681.40 01/19/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 842896663
Principal investigator 1 Incyte Corporation $1,371.00 01/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 831074341
Principal investigator 1 Incyte Corporation $166,865.62 01/13/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831065529
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $58,934.00 01/11/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I II FIH STING Monotherapy Combination in advanced solid tumors No dispute reported 06/30/2026 819882225
Principal investigator 1 Eli Lilly and Company $362,205.57 01/04/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 819449771